Equities analysts predict that Aptevo Therapeutics Inc (NASDAQ:APVO) will post earnings of ($0.59) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Aptevo Therapeutics’ earnings. The highest EPS estimate is ($0.58) and the lowest is ($0.60). Aptevo Therapeutics posted earnings per share of $0.14 during the same quarter last year, which suggests a negative year over year growth rate of 521.4%. The business is scheduled to report its next earnings report on Thursday, November 8th.

On average, analysts expect that Aptevo Therapeutics will report full year earnings of ($2.42) per share for the current year, with EPS estimates ranging from ($2.47) to ($2.36). For the next year, analysts expect that the business will report earnings of ($2.35) per share, with EPS estimates ranging from ($2.68) to ($2.02). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Aptevo Therapeutics.

Aptevo Therapeutics (NASDAQ:APVO) last posted its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.58) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.07. The business had revenue of $6.83 million during the quarter, compared to the consensus estimate of $4.17 million. Aptevo Therapeutics had a negative return on equity of 45.53% and a net margin of 74.01%.

A number of analysts have weighed in on the company. LADENBURG THALM/SH SH assumed coverage on Aptevo Therapeutics in a report on Monday, November 5th. They set a “buy” rating and a $14.00 price target for the company. ValuEngine downgraded Aptevo Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, July 30th. Zacks Investment Research upgraded Aptevo Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price target for the company in a report on Tuesday, August 14th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $11.00 price target on shares of Aptevo Therapeutics in a report on Friday, August 10th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Aptevo Therapeutics has a consensus rating of “Buy” and a consensus target price of $10.69.

NASDAQ APVO opened at $3.36 on Wednesday. The firm has a market capitalization of $78.66 million, a P/E ratio of -2.20 and a beta of 2.27. Aptevo Therapeutics has a twelve month low of $2.54 and a twelve month high of $6.35. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.66 and a quick ratio of 3.50.

A number of institutional investors have recently modified their holdings of the business. Acadian Asset Management LLC grew its holdings in Aptevo Therapeutics by 20.2% during the 3rd quarter. Acadian Asset Management LLC now owns 441,765 shares of the biotechnology company’s stock worth $2,244,000 after acquiring an additional 74,256 shares during the period. Northern Trust Corp boosted its position in shares of Aptevo Therapeutics by 21.2% during the 2nd quarter. Northern Trust Corp now owns 70,416 shares of the biotechnology company’s stock worth $352,000 after purchasing an additional 12,299 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Aptevo Therapeutics by 53.3% during the 2nd quarter. Renaissance Technologies LLC now owns 1,149,400 shares of the biotechnology company’s stock worth $5,736,000 after purchasing an additional 399,400 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Aptevo Therapeutics by 10.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,351,656 shares of the biotechnology company’s stock worth $6,745,000 after purchasing an additional 131,804 shares in the last quarter. Finally, EAM Investors LLC bought a new position in shares of Aptevo Therapeutics during the 2nd quarter worth about $552,000. Hedge funds and other institutional investors own 33.09% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.

Further Reading: Hedge Funds Explained

Get a free copy of the Zacks research report on Aptevo Therapeutics (APVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.